FDA approves pacritinib for intermediate- or high-risk myelofibrosis with severe thrombocytopenia
Last Updated: Friday, March 4, 2022
Based on data from the phase 3 PERSIST-1 and PERSIST-2 trials, as well as from the phase 2 PAC203 trial, the FDA granted accelerated approval to JAK2 inhibitor pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L.
Advertisement
News & Literature Highlights
